Company managing director KRN Moorthy told DNA that the firm’s contract research and manufacturing (CRAMS) business, which currently brings in between 20 and 430 per cent of its annual revenues, “[is] expected to]every year henceforth.”
Moorthy added that the prediction is based on India’s continually growing strength as an outsourcing destination. The country’s contracting market is estimated to be worth some $51bn and is expected to expand 13 per cent a year for the foreseeable future.
CRAMS, in combination with Wanbury's active pharmaceutical ingredient manufacturing (API)business, are expected to generate turnover of some RS4bn.
